Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment?

Bibliography

• Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991;83(1):13-25
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471-6
   PubMed Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74(1):34-41
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Habata Y, Fukusumi S, Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538(2-3):162-71
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54(3):598-604
   PubMed Web of Science ®Google Scholar
• Boucher J, Masri B, Daviaud D, Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146(4):1764-71
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91(5):434-40
   PubMed Web of Science ®Google Scholar
• Ashley EA, Powers J, Chen M, The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005;65(1):73-82
   PubMed Web of Science ®Google Scholar
• Berry MF, Pirolli TJ, Jayasankar V, Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004;110(11 Suppl 1):II187-93
   PubMed Web of Science ®Google Scholar
• Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006;553(1-3):222-8
   PubMed Web of Science ®Google Scholar
• Farkasfalvi K, Stagg MA, Coppen SR, Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007;357(4):889-95
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Takayama K, Zou MX, The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99(2-3):87-92
   PubMedGoogle Scholar
• Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003;470(3):171-5
   PubMed Web of Science ®Google Scholar
• Salcedo A, Garijo J, Monge L, Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept 2007;144(1-3):50-5
   PubMedGoogle Scholar
• Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132(6):1255-60
   PubMed Web of Science ®Google Scholar
• Chen MM, Ashley EA, Deng DX, Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108(12):1432-9
   PubMed Web of Science ®Google Scholar
• Falcao-Pires I, Goncalves N, Henriques-Coelho T, Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009;296(6):H2007-14
   PubMed Web of Science ®Google Scholar
• Castan-Laurell I, Boucher J, Dray C, Apelin, a novel adipokine over-produced in obesity: friend or foe? Mol Cell Endocrinol 2005;245(1-2):7-9
   PubMed Web of Science ®Google Scholar
• Daviaud D, Boucher J, Gesta S, TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006;20(9):1528-30
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13: (Suppl 1):1-68
   PubMedGoogle Scholar
• Lang RM, Bierig M, Devereux RB, Recommendations for chamber quantification. Eur J Echocardiogr 2006;7(2):79-108
   PubMed Web of Science ®Google Scholar
• Oh JK, Taliercio CP, Holmes DR Jr, Prediction of the severity of aortic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. J Am Coll Cardiol 1988;11(6):1227-34
   PubMed Web of Science ®Google Scholar
• Zoghbi WA, Farmer KL, Soto JG, Accurate noninvasive quantification of stenotic aortic valve area by Doppler echocardiography. Circulation 1986;73(3):452-9
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Boulanger CM, Crijns FR, Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95(8):4630-4
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Carabello BA, Faxon DP, ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52(8):676-85
   PubMed Web of Science ®Google Scholar
• Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006;41(5):798-806
   PubMed Web of Science ®Google Scholar
• Xiao HD, Fuchs S, Bernstein EA, Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. Am J Physiol 2008;294(2):H659-67
   Google Scholar
• Jia YX, Pan CS, Zhang J, Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 2006;133(1-3):147-54
   PubMedGoogle Scholar
• Kuba K, Zhang L, Imai Y, Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007;101(4):e32-42
   PubMed Web of Science ®Google Scholar
• Foldes G, Horkay F, Szokodi I, Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308(3):480-5
   PubMed Web of Science ®Google Scholar
• Goetze JP, Rehfeld JF, Carlsen J, Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006;133(1-3):134-8
   PubMedGoogle Scholar
• Chong KS, Gardner RS, Morton JJ, Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8(4):355-60
   PubMed Web of Science ®Google Scholar
• Miettinen KH, Magga J, Vuolteenaho O, Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept 2007;140(3):178-84
   PubMedGoogle Scholar
• Dray C, Knauf C, Daviaud D, Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008;8(5):437-45
   PubMed Web of Science ®Google Scholar
• Erdem G, Dogru T, Tasci I, Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116(5):289-92
   PubMed Web of Science ®Google Scholar